ognizant Communication Corporation

ONCOLOGY RESEARCH
AN INTERNATIONAL JOURNAL
INCORPORATING ANTI-CANCER DRUG DESIGN

AUTHOR AND SUBJECT INDEXES

VOLUME 17

Author Index

AUTHOR INDEX
Abbondanza, C., 33
Acquati, F., 69
Agarwal, A., 127
Akutsu, M., 137
Aldinucci, D., 103
Amato, A., 115
Amirghofran, Z., 447
Andrzejewski, T., 257
Antonaci, A., 495
Arbab, A. S., 257
Asawakarn, S., 301
Aurello, P., 405

Bae, K.-H., 601
Barkhout, M., 347
Bauer, S. M., 205
Bechi, P., 559
Beder, L., 273
Begum, F. D., 43
Bellagamba, R., 405
Bertollo, C. M., 473
Bhagat, M., 387
Bid, H. K., 367
Biswas, D., 397
Blaakær, J., 43
Bonovolias, I. D., 535
Bordonaro, M., 1
Borkosky, S. S., 273
Bose, C. K., 231
Bozkurt, B., 353
Burns, A. J., 93

Cao, T., 373
Cattaruzza, L., 103
Chakrabarti, S., 397
Chan, C.-K., 283
Chandra Mohan, K. V. P., 75, 193
Chang, L.-S., 311
Charbonneau, M., 223
Chashoo, G., 387
Chatterjee, S., 397
Chattopadhyay, N., 367
Chaturvedi, R., 127
Chaudhary, P., 367
Chen, D., 621
Chen, G., 183
Chi, S.-G., 571
Chi, S.-W., 601
Chiani, M., 549
Chien, C.-M., 311
Chiu, C.-C., 311
Choi, E. Y., 23
Christensen, L., 43
Ciardi, A., 405
Cicchini, C., 405
Cipriani, G., 559
Colombatti, A., 103
Consorti, F., 495
Correa, C. R., 473
Crisci, A., 565
Cutts, S. M., 283

Daneshbod, Y., 447
Dang, Y.-W., 183
D'Angelo, F., 405
Danova, K., 51
Danyluk, A., 257
Deeb, D., 257
Della Melina, A., 565
Delmani, F. A., 425
Del Monte, S. R., 405
de Metz, M., 323
Demirkazik, A., 455
Deng, C., 613
de Nigris, F., 33
De Rosa, C., 33
Devlin, A. H., 93
Di Leonardo, A., 115
Do, S.-I., 269
Dong, H., 373
Dulchavsky, S. A., 257
Dutta, S., 387

Elhan, A. H., 455
Ergul, G., 353
Eun, J. R., 23

Fang, J., 437
Feng, Z.-B., 183
Fregona, D., 103
Fujioka, M., 593
Fukushima, M., 137
Furukawa, Y., 137

Gao, J.-L., 519
Gao, X., 257
García-Herdugo, G., 425
Gardiner, T. A., 93
Garg, V. K., 127
Gautam, S. C., 257
Gelboin, H. V., 75, 193
Gholijani, N., 447
Ghoshal, U. C., 167
Giovagnini, L., 103
Giovannone, G., 495
Goes, A. M., 473
Goi, T., 593
Gomez-Santos, L., 437
González-Víltchez, F., 425
Goto, H., 581
Grifoni, R., 559
Groenendaal, N., 323
Guan, L., 373
Gümüs-Akay, G., 455
Gunduz, E., 273
Gunduz, M., 273
Gur-Dedeoglu, B., 353

Han, B., 373
Hanibuchi, M., 581
Hara, Y., 75, 193
Harata, Y., 247
Hatipoglu, O. F., 273
Hayashi, Y., 11
Higashi, N., 437
Hirabayashi, K., 137
Hirono, Y., 593
Hiroshima, K., 239
Hirst, D. G., 93
Høgdall, C. K., 43
Høgdall, E. V., 43
Howell, A. P., 205
Hu, Y., 59
Hua, F., 373
Huang, H., 175, 621
Huo, Q., 217
Hyun, M. S., 23

Igarashi, S., 137
Ikuta, K., 581
Inoue, K., 137
Insalaco, L., 115
Ioannou, M. G., 413
Irimura, T., 437
Izawa, R., 437
Izumi, T., 137

Jacobs, I. J., 43
Jain, M., 87, 167
Jang, B. I., 23
Jin, Y., 59

Kakeya, H., 11
Kakiuchi, S., 581
Kakumoto, M., 527
Kamiyama, H., 11
Kang, M.-J., 571
Kang, S., 601
Kano, Y., 137
Kast, R. E., 383
Katano, S., 137
Katase, N., 273
Katayama, K., 593
Kim, D. S., 601
Kim, H., 331
Kim, H. S., 151
Kim, J. H., 23
Kim, J.-R., 23
Kim, M., 601
Kim, M. K., 23
Kim, S. E., 331
Kim, S. H., 601
Kim, S. W., 23
Kim, T. N., 23
Kim, Y., 601
Kim, Y. H., 571
Kim, Y. W., 269
Kinugasa, T., 217
Kirito, K., 137
Kjær, S. K., 43
Kobayashi, H., 137, 527
Konu, O., 353
Konwar, R., 367
Koukoulis, G. K., 413
Kuman, S., 167, 367
Kuriyama, T., 239
Kuroki, M., 217
Kuroki, M., 217
Lazarova, D. L., 1

Lee, D. H., 601
Lee, E. S., 151
Lee, K. H., 23
Lee, S. C., 601
Lee, S. M.-Y., 519
Lee, W. C., 339
Lee, W. W., 331
Lee, Y. M., 151
Lefeuvre, M., 273
Lentini, L., 115
Lin, K.-L., 311
Lin, S.-R., 311
Logan, I. D., 93
Lorenzon, D., 103
Lo Russo, G., 69
Luo, D.-Z., 183

Malekzadeh, K., 159
Mardente, S., 495
Mashayekhi, R., 549
Mathus-Vliegen, E. M. H., 347
McKeown, S. R., 93
Mirsattari, D., 549
Mishra, D., 367
Mitra, A. K., 127
Mittal, B., 87, 167
Miwa, N., 247
Mohebbi, S. R., 549
Molaei, M., 549
Molinara, E., 559, 565
Momparler, L. F., 223
Momparler, R. L., 223
Monti, L., 69
Moreno, J., 425
Mukherjee, A., 387

Nagai, N., 273
Nagashima, T., 137
Nagatsuka, H., 273
Nagengast, F. M., 323, 347
Nagini, S., 75, 193, 483
Najjar Sadeghi, R., 549
Nakamura, M., 239
Napoli, C., 33
Neri, B., 559, 565
Nicita, G., 565
Nishikawa, K., 11
Nishioka, Y., 581
Nodera, Y., 437
Noonan, D., 69
Nudelman, A., 283

Ogino, H., 581
Oh, S.-H., 339
Ohashi, Y., 437
Ohmine, K., 137
Ohnishi, N., 527
Okayasu, H., 247
O'Keeffe, M. B., 93
Okumura, K., 527
Osada, H., 11
Otsuka, S., 581
Ozawa, K., 137

Pan, C., 621
Pan, H., 373
Pan, J.-J., 339
Pantaleo, P., 559, 565
Pantalone, D., 559
Park, B. C., 601
Park, H. C., 571
Park, H.-R., 269
Park, S. G., 601
Park, S.-H., 151
Park, S. Y., 331
Park, Y.-K., 269
Park, Y.-N., 151
Peters, W. H. M., 323, 347
Petersen, B. E., 339
Phillips, D. R., 283
Poddar, S., 397
Prawettongsopon, C., 301
Puca, G. A., 33

 

Ramacciato, G., 405
Rangan, S., 559, 565
Rath, S. K., 127
Raugei, A., 565
Ravaioli, M., 405
Raynal, N. J.-M., 223
Ren, Y., 373
Rephaeli, A., 283
Rodolfo, M., 69 (191)
Roelofs, H. M. J., 323, 347
Rossiello, R., 33
Ryan, A., 43

Sachan, R., 87
Saini, R. K., 505
Saitoh, Y., 247
Sakaeda, T., 527
Sanyal, S. N., 505
Sanyal, T., 387
Sartorelli, A. C., 1
Sato, K., 137
Sawaguchi, T., 437
Saxena, A. K., 387
Schillaci, T., 115
Schwarz, E., 205
Seckin, S., 353
Sengupta, B., 397
Sengupta, S., 397
Senthil Murugan, R., 483
Sharma, M., 127
Shekari, M., 159
Shen, S., 463
Shi, J.-M., 519
Shibaguchi, H., 217
Shim, H. K., 331
Shimada, H., 239
Shimizu, K., 273
Shoji, M., 11
Simkova, I., 51
Singh, A., 127
Singh, H., 87
Singh, N., 127
Smith, E. S., 205
Sobti, R. C., 159
Son, M. S., 571
Sone, S., 581
Song, S. K., 23
Stegeman, J. J., 75, 193
Sunguroglu, A., 455
Suri, V., 159
Suthiphongchai, T., 301

Tada, Y., 239
Taddei, A., 559
Tagawa, M., 239
Takahashi, T., 581
Takami, N., 217
Takara, K., 527
Takeuchi, H., 437
Takiguchi, Y., 239
Talukder, G., 397
Tamamura, R., 273
Tamandani, D. M. K., 159
Tanaka, M., 137
Tanaka, T., 217
Tang, X.-L., 183
Tanigawara, Y., 527
Taramelli, R., 69
Tatsumi, K., 239
te Morsche, R. H. M., 323, 347
Teramukai, S., 137
Tominaga, S., 273
Tonelli, P., 559
Torreblanca, J., 425
Tsiftsoglou, A. S., 535
Tsunoda, S., 137
Tükün, A., 455

Ueno, S., 437
Ueyama, T., 239
Ugarenko, M., 283
Uhm, K.-O., 151
Ünal, A. E., 455
Upadhyay, R., 167
Urban, L., 51
Urbanova, D., 51
Usami, K., 437
Usui, T., 11

Vageli, D., 413
Vahedi, M., 549
Valeri, A., 559
van der Logt, E. M. J., 323
van der Stappen, J. W., 323
Vannini, A., 559
Vidjaya Letchoumy, P., 75, 193
Vilaplana, R., 425
Villari, D., 565
Vinothini, G., 483

Wang, A., 175, 621
Wang, H., 59
Wang, J., 621
Wang, L., 217
Wang, Y.-T., 519
Wei, W., 373
Williams, M. A., 205

Xiao, J., 613
Xiao, L., 247
Xu, C., 373
Xu, Y., 59, 463

Yamada, T., 581
Yamaguchi, A., 593
Yamanaka, N., 273
Yang, T., 373
Yang, Y., 373
Yano, S., 581
Ying, X., 59
Yokoyama, T., 527
Yu, F., 463
Yulug, I. G., 353

Zali, M. R., 549
Zauderer, M., 205
Zeng, R., 175
Zhang, B., 621
Zhang, Q.-W., 519
Zhao, J., 217
Zojaji, H., 549
Zou, Q., 59

 

Subject Index

Acute lymphoblastic leukemia, 447
Acute myeloid leukemia, 103
Acute promyelocytic leukemia-derived NB4 cells, 373
Adenovirus, 239
Aggressive lymphoma, 137
Akt, 257
All-trans retinoic acid, 175
Ambrisentan, 383
AN-9, 283
Androgen independent, 301
Aneuploidy, 115
Angiogenesis, 93, 193, 519
Anthracyclines, 51
Antiangiogenesis, 11
Antibody-dependent cellular cytotoxicity (ADCC), 217
Anticancer drug, 527
Antineoplastic agents, 103
Antioxidants, 193
Antitumor, 11
Antitumor agent, 387
Antitumor drugs, 425
Antitumorigenic activity, 69
aPCK inhibitor, 59
Apoptosis, 1, 23, 257, 301, 373, 483, 495, 613
Aurora A/STK15, 115
5-Aza-2´-deoxycytidine, 223

BAD, 23
Base excision repair (BER), 127
B cell, 463
Bcl-2, 447
Bcl-2 family, 373
Bcr-Abl kinase, 535
B16 Differential in-gel electrophoresis (DIGE), 601
Berberine, 519
Beta-catenin, 1
Black tea polyphenols, 75
Bladder tumor, 93
Bmi-1, 613
Bone marrow, 339
Bone metastasis model, 581
Borderline ovarian tumors, 43
Breast cancer, 353, 367, 473, 483
Butyrate, 1

Cancer, 33, 205
Cancer risk, 167
Cancer susceptibility, 167
Carcinoembryonic antigen (CEA), 217
Carcinogen activation, 193
Cardiotoxicity, 51
Cardiotoxin III, 311
C57BL/6 mouse, 463
CD40, 463
Cell cycle, 175
Cell line, 473
Cell proliferation, 193, 483
Centrosome amplification, 115
Cervical cancer, 87, 159
Characterization, 473
Chemokine receptor, 87
Chemoprevention, 75, 193
Chemotherapy, 223, 559, 565
Cholangiocarcinoma, 151
Chronic lymphocytic thyroiditis, 495
CIN, 115
Clinical trial, 239
CML cell, 535
CNS lymphoma, 137
Colorectal cancer, 1, 323, 593
Colorectal carcinoma cells, 437
Confidence interval, 127
Corydalis yanhusuo, 519
Curcumin, 257
Cyclooxygenase-2, 347
Cytotoxicity, 387

DCIK/DCIK-P cells, 59
Dendritic cells, 205
Digoxin, 527
9/10-Dimethylbenz[a]anthracene, 505
Dkk-3, 273
DMBA, 75
Docetaxel, 565
Doxazosin, 527
Doxorubicin, 283
Drug resistance, 223
Duodenal adenomatosis, 347
 
 
 
 
 

 

EGF-EGFR interactions, 167
Endogenous reference genes, 353
Endothelin, 383
Epigenetic, 223
Epirubicin, 565
Epithelial ovarian cancer (EOC), 231, 383
Eposyquinoid, 11
ER81, 413
Esophageal cancer, 167
Establishment, 473

Familial adenomatous polyposis, 347
FDG-PET, 331
Fibrillarin, 425
Follicle stimulating hormone receptor (FSHR), 231
Formaldehyde, 283
Frequency, 43
5-FU, 59
Fusion proteins, 205

Gastric cancer, 455, 549, 571
Gastric carcinoma, 405, 613
Gastritis, 549
G-CSF, 137
Gemcitabine, 559
Gene polymorphism, 397
Gene therapy, 239, 621
Genetic polymorphism, 87, 323, 347
Genetic susceptibility, 87
Genistein, 223
Genomic imbalances, 455
Global genome methylation, 549
Glucose transporter, 331
Glut-1, 93

Hamster buccal pouch carcinogenesis, 75
hASIP, 59
Head and neck squamous cell carcinoma, 273
Hemin, 535
Heparanase, 183
Hepatic asialoglycoprotein receptor, 437
Hepatocellular carcinoma, 183, 463
Hepatocyte growth factor (HGF), 23
Her2, 413
Hexokinase, 331
Histone deacetylase inhibitors, 1
Hodgkin lymphoma, 331
HR-CGH, 455
hTERT, 413
Human breast cancer, 59
Human oral squamous cell carcinoma (OSCC), 175
Human telomerase reverse transcriptase, 621
Human tongue carcinoma, 247
HUVEC, 519
Hypermethylation, 151, 571
Hypomethylation, 549
Hypoxia, 93

IgA, 217
IGF-II, 269
IL-1RN, 367
IL-4, 367
Imatinib mesylate, 535
Immunohistochemistry, 183
Immunotherapy, 217, 463
IMP3, 269
Interleukin-18, 159
Invasion, 301
In vivo assay, 387
Irinotecan, 559

KOC, 269

L523S, 269
Lentiviral vector, 621
Leukemia, 223
Liver metastasis, 437
Loss of heterozygosity, 273
Lung adenocarcinoma, 581

MCF-7 cells, 301
MDR1/P-glycoprotein, 527
Medicinal inorganic chemistry, 103
Melanoma, 601
Melanoma model, 69
Mesothelioma, 239
Metaplasia, 383
Metastasis, 301, 601
Methylation-specific PCR, 151
Mice lung tumorigenesis, 505
Microenvironment, 339
Micrometastases, 383
Microsatellite instability, 43
Microsatellite instability-high, 43
Microsatellite instability-low, 43
Microvessel density (MVD), 93, 405
Mitogen activated protein kinase (MAPK), 23
MSI, 549
Multidrug resistance, 527
Mutation, 397
Myeloid antigens, 447

Natriuretic peptides, 51
Neutral pH hydrogen-enriched electrolyzed water, 247
Neutrophils, 217
New nitrosourea, 387
NF-kB, 257, 301
Nonsteroidal anti-inflammatory drugs, 505
Normalization factor, 353
North Indian women, 127

Odds ratio, 127
8-OH-dG, 75
Oncogenes, 495
Oral cancer, 397
Oral squamous cell carcinoma, 621
Organ microenvironment, 437
Osteoblastic bone metastasis, 581
Osteolytic bone metastasis, 581
Osteosarcoma, 33, 269
Ovarian cancer, 43
Ovarian surface epithelium (OSE), 231
Oxidative stress, 483

11p15.2, 273
Palladium compounds, 103
Pancreatic cancer, 339, 559
Papillary thyroid carcinoma, 495
PCR, 273
PCR-SSP, 159
Pericyte, 93
Phosphoinositide 3-kinase (PI3K), 23
PI3K, 301
Pluronics, 283
Polymorphism, 159, 367
Population, 397
Progenitor cell, 339
Proliferation, 613
Prostate cancer, 257, 301
Prostate carcinoma, 565
Protection, 535
Proteomics, 601
Pyrosequencing, 549

Q-RT real-time PCR, 413 

RAP, 425
Reactive oxygen species, 247, 373
Real-time quantitative RT-PCR, 353
Relative risk, 127
Reversal, 527
RIN1 gene, 593
Risk, 367
RIZ, 33
RNA interference (RANi), 613, 621
RNASET2

Single nucleotide polymorphism (SNP), 127
Sodium butyrate, 175
Sodium selenite, 373
Splicing variant, 593

Tazarotene-induced gene 1 (TIG1), 571
TCC-NHL-91, 137
Telomerase activity, 455
Telomerase regulation, 455
Therapeutic index, 103
Tissue microarray, 183
Tobacco, 397
Toxicological assay, 387
TRAIL, 257
Tumor cells, 387
Tumor repression, 247
Tumor suppressor gene, 69, 151, 273
Tumorigenesis, 339

UBF, 425
UDP-glucuronosyltransferase 2B7, 323
Ultrasound, 283
Urothelial carcinoma, 93

Vascular endothelial growth factor (VEGF), 11, 405
VEGF-C, 405

Weekly regiman, 565
Whole protein extracts, 425
Wnt, 1

Xenobiotic-metabolizing enzymes, 75

YY1, 33